Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)

NCT05372939 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: AMT-101 (oral)
OTHER: Placebo (oral)
COMBINATION_PRODUCT: Humira (adalimumab)

Sponsor

Applied Molecular Transport